The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Abstract
Background Most patients with obsessive-compulsive disorder (OCD) show only partial reduction of symptoms with standard therapy. Recent imaging data suggests glutamatergic dysfunction in the corticostriatal pathway in OCD. We investigated the efficacy of augmentation therapy with riluzole, a glutamate-modulating agent, in treatment-resistant OCD.Methods Thirteen patients aged between 18 and 65 years with a primary diagnosis of OCD that had proven resistant to standard treatment were treated with the addition of riluzole to their existing pharmacotherapy. Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Hamilton Depression Inventory (HAM-D), and Hamilton Anxiety Inventory (HAM-A) scores were obtained weekly.Results Thirteen treatment-resistant OCD patients received riluzole 50 mg twice a day. Y-BOCS scores improved significantly over time. Of 13 patients, 7 (54%) demonstrated a >35% reduction in Y-BOCS scores, and 5 (39%) were categorized as treatment responders. HAM-D and HAM-A scores for the group also significantly improved over time. Riluzole was well tolerated with no serious adverse effects noted.Conclusions Riluzole appears to have significant antiobsessional, antidepressant, and antianxiety properties. The addition of this agent may be of practical clinical benefit in patients with OCD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BDZs, which have been in clinical use for decades, not only exhibit rapid anxiolytic effects, but also have sedative, amnestic, anticonvulsant, muscle relaxant and addictive properties (Coric et al., 2005;Engin et al., 2018).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Coric et al., 2005
In the citing paper
“Riluzole was shown to reduce clinical symptoms in adults with treatment-refractory OCD when used as add-on to existing pharmacotherapy, including SSRIs and antipsychotics (Coric et al., 2005;Pittenger et al., 2015).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Coric et al., 2005
Citations
Cites
Applied Mixed Models in Medicine
Brown, H., & Presco, R. (2000) · Technometrics · doi:10.1080/00401706.2000.10485742 · Cited by 1,699
Gueorguieva, R., & Krystal, J. H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.3.310 · Cited by 1,529
Magistretti, P. J., Pellerin, L., Rothman, D. L., & Shulman, R. G. (1999) · Science · doi:10.1126/science.283.5401.496 · Cited by 1,170
Subtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients With Major Depression
Sanacora, G., Gueorguieva, R. V., Epperson, C. N., Wu, Y., Appel, M., Rothman, D. L., Krystal, J. H., & Mason, G. F. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.705 · Cited by 796
Auer, D. P., Pütz, B., Kraft, E., Lipinski, B., Schill, J., & Holsboer, F. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00159-6 · Cited by 562
Neurobiology of Mental Illness
(2011) · Oxford University Press eBooks · doi:10.1093/med/9780199798261.001.0001 · Cited by 523
Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13 C NMR
Shen, J., Petersen, K. F., Behar, K. L., Brown, P., Nixon, T. W., Mason, G. F., Petroff, O. A. C., Shulman, G. I., Shulman, R. G., & Rothman, D. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.8235 · Cited by 462
The Physicians' Desk Reference
Cohen, J. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440120021003 · Cited by 430
Riluzole inhibits the persistent sodium current in mammalian CNS neurons
Urbani, A., & Belluzzi, O. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00242.x · Cited by 381
ROSENBERG, D. R., MacMASTER, F. P., KESHAVAN, M. S., FITZGERALD, K. D., STEWART, C. M., & MOORE, G. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200009000-00008 · Cited by 377
Cited by
Sorted by citations
Items 301–313 of 313
Novel Mechanisms of Drug Treatment in Psychiatry
Xia, Z., & Roth, B. L. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-252-6_30
The Undergraduate Research Journal of Psychology of, U. C. L. A. (2024) · The undergraduate research journal of psychology at UCLA. · doi:10.5070/jp2.33575
Anksiyete ve Travmatik Stres Bozuklukları
Gül, V. (2024) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3184
Voderholzer, U., Rubart, A., Kathmann, N., Staniloiu, A., Kordon, A., & Zurowski, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-67878-7_6
Obsesif-Kompulsif Hastalıklar - Tanı ve Tedavileri
Gül, V. (2025) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3672
Innovative treatment approaches for paediatric obsessive-compulsive disorder
Marazziti, D., Gurrieri, R., Gambini, M., Russomanno, G., Palagini, L., & Mucci, F. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2591073
Treatment of anxiety: current status and controversial issues
Simpson, H. B., Neria, Y., Lewis‐Fernández, R., & Schneier, F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.024
Ni, C., Liu, J.-M., Yang, T., Deng, Z., Wu, X., Li, S., Xue, H., Wang, Z., Cao, X., & Zhao, C. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag021
Sylvester, A. L., Spapens, J., Tse, D. H. Y., Serrarens, C., Kappert, S., Soons, N., Poser, B. A., Linden, D. E. J., Ivanov, D., van Amelsvoort, T., et al. (2026) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2026.112279
Hudak, R., Eken, H. N., & Donahue, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27446-6.00006-6
Neurochemistry and neurotransmitters involved in obsessive–compulsive disorder
Grant, J., & Sohl, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27446-6.00004-2
Neuroscience-informed psychoeducation for OCD
McLaughlin, N. C. R., Fedorenko, E. J., & Kulak, M. J. (2026) · Progress in brain research · doi:10.1016/bs.pbr.2026.10.002
Metadata
- Authors
- Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., Malison, R. T., & Krystal, J. H.
- Affiliations
- Yale University (US)
- ORCID
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2005-09
- Volume
- 58
- Issue
- 5
- Pages
- 424-428
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W1982538263
- Cited by
- 314
- References
- 25
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 10 · 2020: 8 · 2019: 12 · 2018: 5 · 2017: 15 · 2016: 15 · 2015: 21 · 2014: 21 · 2013: 22 · 2012: 23
- FWCI
- 25.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k05aa014906-03)
- National Institute on Alcohol Abuse and Alcoholism (K05 AA 14906-01)
- National Center for Research Resources (M01RR000125, M01 RR-00125)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- riluzole, treatment-resistant OCD, augmentation therapy, glutamate modulation, glutamatergic dysfunction, corticostriatal pathway, antidepressant effects, anxiolytic effects, adverse effects
- MeSH terms
- Adult, Drug Resistance, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Time Factors, Treatment Outcome, Excitatory Amino Acid Antagonists, Riluzole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
